Chan, Ariane
Gilfillan, Connie
Templeton, Nikki
Paterson, Ian
Northcote, Peter T.
Miller, John H.
Funding for this research was provided by:
Cancer Society of New Zealand (E1807)
Wellington Medical Research Foundation (E1707)
Victoria University of Wellington (204067)
Genesis Oncology Trust (E1802)
Article History
Received: 25 April 2017
Accepted: 12 July 2017
First Online: 22 July 2017
Compliance with ethical standards
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Peter Northcote and John Miller are named on a 2004 US patent for development of peloruside A as an anticancer agent. Ariane Chan, Connie Gilfillan, Nikki Templeton, and Ian Paterson declare that they have no conflict of interest.
: This research was supported by grant E1807 from the Cancer Society of New Zealand to JHM, PTN, and AC, grant E1707 from the Wellington Medical Research Foundation to JHM and PTN, and grant UGC-204067 from Victoria University of Wellington to JHM and PTN. AC was the recipient of PhD Scholarship E1802 from the Genesis Oncology Trust of New Zealand.